187 related articles for article (PubMed ID: 38463158)
1. Model-based impact evaluation of new tuberculosis vaccines in aging populations under different modeling scenarios: the case of China.
Tovar M; Sanz J; Moreno Y
Front Public Health; 2024; 12():1302688. PubMed ID: 38463158
[TBL] [Abstract][Full Text] [Related]
2. Age-targeted tuberculosis vaccination in China and implications for vaccine development: a modelling study.
Harris RC; Sumner T; Knight GM; Evans T; Cardenas V; Chen C; White RG
Lancet Glob Health; 2019 Feb; 7(2):e209-e218. PubMed ID: 30630775
[TBL] [Abstract][Full Text] [Related]
3. Potential impact of tuberculosis vaccines in China, South Africa, and India.
Harris RC; Sumner T; Knight GM; Zhang H; White RG
Sci Transl Med; 2020 Oct; 12(564):. PubMed ID: 33028708
[TBL] [Abstract][Full Text] [Related]
4. Potential impact of spatially targeted adult tuberculosis vaccine in Gujarat, India.
Shrestha S; Chatterjee S; Rao KD; Dowdy DW
J R Soc Interface; 2016 Mar; 13(116):. PubMed ID: 27009179
[TBL] [Abstract][Full Text] [Related]
5. The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China.
Weerasuriya CK; Harris RC; McQuaid CF; Bozzani F; Ruan Y; Li R; Li T; Rade K; Rao R; Ginsberg AM; Gomez GB; White RG
BMC Med; 2021 Feb; 19(1):60. PubMed ID: 33632218
[TBL] [Abstract][Full Text] [Related]
6. The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study.
Portnoy A; Clark RA; Quaife M; Weerasuriya CK; Mukandavire C; Bakker R; Deol AK; Malhotra S; Gebreselassie N; Zignol M; Sim SY; Hutubessy RCW; Baena IG; Nishikiori N; Jit M; White RG; Menzies NA
PLoS Med; 2023 Jan; 20(1):e1004155. PubMed ID: 36693081
[TBL] [Abstract][Full Text] [Related]
7. NATCON 2022 Panel discussion: "TB vaccination - Going Forward".
Banurekha VV; Padmapriyadarsini C; Bhargava S; Sachdeva K
Indian J Tuberc; 2023 Jul; 70(3):366-369. PubMed ID: 37562914
[TBL] [Abstract][Full Text] [Related]
8. Tuberculosis vaccines and prevention of infection.
Hawn TR; Day TA; Scriba TJ; Hatherill M; Hanekom WA; Evans TG; Churchyard GJ; Kublin JG; Bekker LG; Self SG
Microbiol Mol Biol Rev; 2014 Dec; 78(4):650-71. PubMed ID: 25428938
[TBL] [Abstract][Full Text] [Related]
9. [Recent progress in mycobacteriology].
Okada M; Kobayashi K
Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
[TBL] [Abstract][Full Text] [Related]
10. Is neglect of self-clearance biasing TB vaccine impact estimates?
Scarponi D; Clark RA; Weerasuriya CK; Emery J; Houben RMGJ; White R; McCreesh N
BMJ Glob Health; 2023 Aug; 8(8):. PubMed ID: 37558271
[TBL] [Abstract][Full Text] [Related]
11. Tuberculosis: vaccines in the pipeline.
Ly LH; McMurray DN
Expert Rev Vaccines; 2008 Jul; 7(5):635-50. PubMed ID: 18564018
[TBL] [Abstract][Full Text] [Related]
12. Vaccine development against tuberculosis before and after Covid-19.
Kaufmann SHE
Front Immunol; 2023; 14():1273938. PubMed ID: 38035095
[TBL] [Abstract][Full Text] [Related]
13. New tuberculosis vaccines in India: modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01
Clark RA; Weerasuriya CK; Portnoy A; Mukandavire C; Quaife M; Bakker R; Scarponi D; Harris RC; Rade K; Mattoo SK; Tumu D; Menzies NA; White RG
BMC Med; 2023 Aug; 21(1):288. PubMed ID: 37542319
[TBL] [Abstract][Full Text] [Related]
14. Data-driven model for the assessment of
Arregui S; Iglesias MJ; Samper S; Marinova D; Martin C; Sanz J; Moreno Y
Proc Natl Acad Sci U S A; 2018 Apr; 115(14):E3238-E3245. PubMed ID: 29563223
[TBL] [Abstract][Full Text] [Related]
15. Vaccination Strategies Against Mycobacterium tuberculosis: BCG and Beyond.
Ferluga J; Yasmin H; Bhakta S; Kishore U
Adv Exp Med Biol; 2021; 1313():217-240. PubMed ID: 34661897
[TBL] [Abstract][Full Text] [Related]
16. End-point definition and trial design to advance tuberculosis vaccine development.
Garcia-Basteiro AL; White RG; Tait D; Schmidt AC; Rangaka MX; Quaife M; Nemes E; Mogg R; Hill PC; Harris RC; Hanekom WA; Frick M; Fiore-Gartland A; Evans T; Dagnew AF; Churchyard G; Cobelens F; Behr MA; Hatherill M
Eur Respir Rev; 2022 Jun; 31(164):. PubMed ID: 35675923
[TBL] [Abstract][Full Text] [Related]
17. Trends of type 2 diabetes with pulmonary tuberculosis patients,2013-2022, and changes after the coronavirus disease 2019 (COVID-19) pandemic.
Wang Z; Zhao S; Zhang A; Quan B; Duan C; Liang M; Yang J
Tuberculosis (Edinb); 2024 May; 146():102499. PubMed ID: 38442538
[TBL] [Abstract][Full Text] [Related]
18. Perspectives on development and advancement of new tuberculosis vaccines.
da Costa C; Benn CS; Nyirenda T; Mpabalwani E; Grewal HMS; Ahmed R; Kapata N; Nyasulu PS; Maeurer M; Hui DS; Goletti D; Zumla A
Int J Infect Dis; 2024 Apr; 141S():106987. PubMed ID: 38417616
[TBL] [Abstract][Full Text] [Related]
19. Tuberculosis: Current Status, Diagnosis, Treatment and Development of Novel Vaccines.
Yadav J; Verma S; Chaudhary D; Jaiwal PK; Jaiwal R
Curr Pharm Biotechnol; 2019; 20(6):446-458. PubMed ID: 31208308
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
